Check out our most popular compounded medications! Get Started
The Estradiol 0.6 mg/Estriol 2.4 mg Slow Release (MEM4) Oral Capsules are a hormone replacement therapy (HRT) designed to alleviate symptoms associated with menopause, such as hot flashes, vaginal dryness, and osteoporosis prevention. This formulation combines two estrogens, estradiol and estriol, in a slow-release capsule that ensures a steady delivery of the hormones over an extended period. The use of Methocel E4M, a controlled-release polymer, in these capsules allows for a consistent release of the active ingredients, minimizing fluctuations in hormone levels and enhancing patient comfort by reducing the need for frequent dosing. This formulation is tailored to provide a controlled and prolonged release profile, which can lead to improved patient adherence and overall treatment satisfaction.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
The Estradiol 0.6 mg/Estriol 2.4 mg Slow Release (MEM4) Oral Capsules are a specialized hormone replacement therapy (HRT) designed to alleviate symptoms associated with menopause and other conditions related to estrogen deficiency. This unique formulation combines two forms of estrogen: estradiol, the primary and most potent naturally occurring human estrogen, and estriol, a weaker estrogen that is abundant during pregnancy. The ratio of estriol to estradiol has been carefully selected to provide a balanced effect, with the aim of mimicking the body's natural hormone levels as closely as possible.
The capsules are formulated with Methocel E4M, a hydrophilic methylcellulose derivative that acts as a controlled-release polymer. This excipient swells and forms a gel-like matrix when exposed to gastrointestinal fluids, which slows the release of the active hormones from the capsule. This slow-release mechanism ensures a steady absorption of the hormones over an extended period, which can lead to more stable blood hormone levels and may reduce the incidence of peaks and troughs associated with immediate-release formulations. As a result, patients may experience fewer side effects and a more consistent relief of symptoms.
By utilizing Methocel E4M, the formulation is tailored to release the hormones gradually, which can be particularly beneficial for managing symptoms such as hot flashes, night sweats, vaginal dryness, and mood swings. Additionally, the sustained release of estrogen may have positive effects on bone density, potentially reducing the risk of osteoporosis in postmenopausal women. It is important to note that hormone replacement therapy should be individualized and used at the lowest effective dose for the shortest duration consistent with treatment goals and risks for the individual woman.
For prescribers, it is crucial to consider the patient's medical history, including any risk factors for cardiovascular disease, breast cancer, or thromboembolic disorders, as estrogen therapy may be contraindicated in certain scenarios. Regular monitoring and follow-up are essential to ensure the efficacy and safety of the treatment. For patients, adherence to the prescribed dosing schedule is important to maintain the controlled release of the medication and to achieve the desired therapeutic outcomes. Patients should also be aware of the potential side effects and the importance of reporting any unusual symptoms to their healthcare provider.
If you have any questions or require further information about the Estradiol 0.6 mg/Estriol 2.4 mg Slow Release (MEM4) Oral Capsules, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing comprehensive support and guidance to both patients and prescribers to ensure the optimal use of this formulation.
The Estradiol 0.6 mg/Estriol 2.4 mg Slow Release (MEM4) Oral Capsules are a hormone replacement therapy (HRT) designed to alleviate symptoms associated with menopause, such as hot flashes, vaginal dryness, and osteoporosis prevention. The capsules are formulated with Methocel E4M, a hydrophilic polymer that ensures a controlled and extended release of the hormones, potentially minimizing fluctuations in hormone levels and reducing the frequency of dosing.
When considering the use of this formulation, it is important to be aware of potential drug interactions. Estradiol and estriol, being estrogen hormones, can interact with a variety of medications. For instance, they may reduce the effectiveness of aromatase inhibitors (e.g., anastrozole, letrozole) which are used in the treatment of certain types of breast cancer. Concurrent use with these medications should be approached with caution and may require dosage adjustments or alternative therapies.
Estrogens can also interact with thyroid hormone replacement therapy. They may increase thyroid-binding globulin (TBG) levels, leading to decreased free thyroid hormone levels and necessitating a potential increase in the dose of thyroid replacement therapy. Patients on thyroid hormone replacement should have their thyroid function monitored closely when initiating or adjusting estrogen therapy.
Additionally, estrogens can affect the metabolism of certain drugs by inducing or inhibiting cytochrome P450 enzymes. For example, they may increase the metabolism of substrates of CYP3A4, such as certain benzodiazepines, cyclosporine, and some statins, potentially reducing their effectiveness. Conversely, they may inhibit the metabolism of drugs metabolized by CYP2C19, such as omeprazole and citalopram, leading to increased plasma concentrations of these drugs.
Estrogens may also potentiate the effects of corticosteroids and decrease the response to anticoagulants, like warfarin, requiring careful monitoring and possible dose adjustments. Patients taking anticoagulants should have their coagulation parameters closely monitored, especially when starting or stopping estrogen therapy.
Furthermore, certain antibiotics and antifungal medications, as well as herbal products containing St. John's Wort, may alter the metabolism of estrogens, potentially leading to decreased efficacy or increased risk of side effects. It is important to inform healthcare providers of all medications, including over-the-counter drugs and herbal supplements, being taken concurrently with this HRT formulation.
Lastly, smoking can increase the metabolism of estrogens and reduce their clinical effects, as well as increase the risk of serious cardiovascular side effects, especially in women over 35 years of age. Patients are strongly advised to avoid smoking while taking estrogen-containing medications.
Due to the complexity of hormone therapy and potential drug interactions, it is crucial for prescribers to review a patient's complete medication profile before initiating treatment with Estradiol 0.6 mg/Estriol 2.4 mg Slow Release (MEM4) Oral Capsules. Patients should be counseled on the importance of reporting any new medications or changes in their health status. For any questions or concerns regarding this formulation and its interactions, please reach out to us at Bayview Pharmacy for further assistance.
The Estradiol 0.6 mg/Estriol 2.4 mg Slow Release (MEM4) Oral Capsules are a specialized formulation designed to deliver a combination of estrogen hormones, estradiol and estriol, in a controlled manner. The capsules are compounded using Methocel E4M, which is a type of hydrophilic polymer known as hypromellose (hydroxypropyl methylcellulose). This polymer is widely used in pharmaceutical formulations to create a slow-release matrix. When the capsule is ingested and comes into contact with gastric fluids, Methocel E4M hydrates and swells to form a gel-like matrix that encapsulates the hormones. This matrix creates a barrier through which the estradiol and estriol must diffuse to be released.
The release of estradiol and estriol from this matrix is a controlled process that occurs over an extended period. As the capsule travels through the gastrointestinal tract, the polymer gradually erodes or the drug slowly diffuses through the hydrated gel layer, maintaining a consistent release rate. This slow release ensures that the hormones are delivered into the bloodstream at a steady rate, mimicking the body's natural hormone release and reducing the fluctuations in hormone levels that can be associated with traditional immediate-release formulations. The sustained release of hormones can lead to improved efficacy and reduced side effects, as well as enhanced patient compliance due to the decreased need for frequent dosing.
Estradiol and estriol are forms of estrogen, a hormone responsible for the regulation of many processes in the female body, including the menstrual cycle and reproductive system. This formulation is typically used in hormone replacement therapy (HRT) for the treatment of menopausal symptoms such as hot flashes, vaginal dryness, and osteoporosis prevention. By providing a steady supply of estrogen, these capsules can help alleviate these symptoms and improve the quality of life for menopausal and postmenopausal women. Additionally, the combination of estradiol and estriol may offer a more balanced approach to HRT, as estriol is considered a weaker estrogen that can potentially reduce the risks associated with estrogen therapy.
It is important for both patients and prescribers to understand the pharmacokinetics and pharmacodynamics associated with this formulation. The slow-release mechanism allows for once-daily dosing, which can improve adherence to the medication regimen. However, individual patient factors such as gastrointestinal transit time, pH, and the presence of food can affect the release rate of the hormones. Prescribers should consider these factors when determining the appropriateness of this formulation for their patients. Additionally, monitoring of hormone levels and patient symptoms is recommended to ensure the optimal dose is being administered for the desired therapeutic effect.
If you have any questions or require further information about the Estradiol 0.6 mg/Estriol 2.4 mg Slow Release (MEM4) Oral Capsules, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide support and guidance to ensure the best possible outcomes for our patients and prescribers.
MEM4 Oral Capsule is a compound formulation that contains two estrogens, Estradiol at a dose of 0.6 mg and Estriol at a dose of 2.4 mg. It's designed to be a bioidentical hormone replacement therapy (HRT) that provides a slow, controlled release of these hormones over an extended period of time.
The MEM4 Oral Capsule is formulated with Methocel E4M, a controlled-release polymer that allows the medication to be released gradually over time. This slow-release mechanism ensures sustained therapeutic effects and reduces the need for frequent dosing, potentially improving patient compliance.
The dosing frequency of MEM4 Oral Capsules may vary depending on individual treatment plans and the advice of a healthcare provider. Due to the slow-release properties of the capsules, they are typically taken less frequently than immediate-release formulations. Your doctor will prescribe the appropriate dosing schedule for you.
MEM4 Oral Capsule is designed for slow and sustained hormone release, and therefore may not provide immediate symptom relief. It is intended to maintain stable hormone levels over time, which can help manage menopausal symptoms over the long term rather than providing quick relief.
It is important to store MEM4 Oral Capsules at room temperature away from moisture, heat, and direct light. Always keep the medication in its original container and out of reach of children and pets. Consult the pharmacy label or your pharmacist for more specific storage instructions.
MEM4 Oral Capsules offer the benefit of a controlled, slow release of medication, which can lead to more stable blood hormone levels and may reduce the frequency of the peaks and troughs associated with traditional hormone therapies. This can result in a smoother experience with fewer side effects and increased convenience due to reduced dosing frequency.
As with any medication, there may be interactions when using MEM4 Oral Capsules with other drugs. It's essential to inform your healthcare provider of all medications and supplements you are taking to determine if MEM4 Oral Capsules are safe to use in combination with your current medications.
Opening or breaking the MEM4 Oral Capsules is not recommended, as it can interfere with the slow-release mechanism of the medication. If you have difficulty swallowing pills, please discuss alternative options with your healthcare provider.
If you miss a dose of MEM4 Oral Capsules, take it as soon as you remember. However, if it's close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double up on doses to make up for a missed one. For personalized advice, talk to your healthcare provider.
As with any medication, MEM4 Oral Capsules may cause side effects. Some common side effects include nausea, headache, breast tenderness, and bloating. If you experience any severe or persistent side effects, contact your healthcare provider immediately.
MEM4 Oral Capsules may not be suitable for everyone. Women with a history of certain health conditions such as breast cancer, liver disease, or blood clots should not use this medication. Always discuss your health history with your healthcare provider before starting any new medication, including MEM4 Oral Capsules.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
